PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade

Regenerative lineages and immune-mediated pruning in lung cancer metastasis

(2020) Ashley M. Laughney et al.   NATURE MEDICINE

A Variant of a Killer Cell Immunoglobulin-like Receptor is Associated with Resistance to PD-1 Blockade in Lung Cancer

(2019) Marcel P Trefny et al.   CLINICAL CANCER RESEARCH

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

(2019) Laurent Gauthier et al.   CELL

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

(2019) Edward B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

(2018) Kevin C. Barry et al.   NATURE MEDICINE

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

(2018) Scott J. Rodig et al.   Science Translational Medicine

Gas chromatography‑time of flight/mass spectrometry‑based metabonomics of changes in the urinary metabolic profile in osteoarthritic rats

(2018) Hui Jiang et al.   Experimental and Therapeutic Medicine

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

(2018) Joy Hsu et al.   JOURNAL OF CLINICAL INVESTIGATION

Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells

(2018) Linda Quatrini et al.   NATURE IMMUNOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization

(2017) Silvia Pesce et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers

(2017) Y Liu et al.   ONCOGENE

Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more

(2017) Laura Chiossone et al.   SEMINARS IN IMMUNOLOGY

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

(2016) Xin-guang Liu et al.   IMMUNOLOGICAL INVESTIGATIONS

Targeting natural killer cells in cancer immunotherapy

(2016) Camille Guillerey et al.   NATURE IMMUNOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma

(2016) Asma Beldi-Ferchiou et al.   Oncotarget

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells

(2015) Pamela M. Odorizzi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

(2015) D. S. Thommen et al.   Cancer Immunology Research

Effect of tumor cells and tumor microenvironment on NK-cell function

(2014) Massimo Vitale et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade

(2014) I. P. da Silva et al.   Cancer Immunology Research

Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin

(2013) R. Remark et al.   CLINICAL CANCER RESEARCH

Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells

(2012) S. Gill et al.   BLOOD

Melanoma Cells Inhibit NK Cell Functions--Letter

(2012) G. Sconocchia et al.   CANCER RESEARCH

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

(2011) S. Platonova et al.   CANCER RESEARCH

Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD

(2011) Silke Wiesmayr et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

(2011) Nicolas F Delahaye et al.   NATURE MEDICINE

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Regulation of human NK-cell cytokine and chemokine production by target cell recognition

(2009) C. Fauriat et al.   BLOOD

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells

(2008) Paolo Carrega et al.   CANCER

Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors

(2008) Daniela Zychlinski et al.   MOLECULAR THERAPY